Pipeline

In order to demonstrate the diversity of the AMR-dedicated SMEs’ pipeline in Europe, the BEAM Alliance has collated its members’ technological assets into a comprehensive portfolio. While its size is already impressive, the proposed categorization approach is further revealing the high level of innovativeness that is being deployed, both at clinical and preclinical stages.

BEAM Infection Curve (BIC)

BEAM Infection Curve (BIC)

Pipeline Rx

Click on column headers to sort the table

memberproductbic*typetargets/indicationsdevelopment
stage
Eligo BioscienceEB0034aPhageHemolytic uremic syndrome (HUS)IND/CTA ready
OM Pharma SAUro-Vaxom®1aOtherRecurrent lower urinary tract infections (i.e. cystitis)Marketed
OM Pharma SABroncho-Vaxom® (Bacterial Lysates – OM-85)1aOtherRecurrent Respiratory Tract Infections (RTIs)Marketed
OM Pharma SAOM-851aOtherRespiratory Tract Infections (RTIs)Phase II
OM Pharma SAOM-891aOtherCommunity acquired pneumonia (CAP) and other upper respiratory infections (URTI) (sinusitis/otitis media etc)Phase I
OM Pharma SAOM-851aOtherUncomplicated urinary tract infections (uUTI)Phase I
DevsHealth SLMulti-resistant s. aureus novel treatmentNMES. aureus (methicillin resistant) / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Discovery
ArrePathAP-0013aNMEE. coli, K. pneumoniae, Enterobacter spp., Citrobacter spp., Other Enterobacterales, Salmonella spp., Shigella spp., E. faecium, N. gonorrhoeae, H. influenzae / Complicated urinary tract infections (cUTI)Lead opt
Tabrixanti-virulence agents3aNMEMycobacterium tuberculosis / Cystic fibrosis associated infectionsIND/CTA ready
GranulyticsUndisclosed3aProtein/PeptideE. coli, S. aureusPre-clinical
Santero TherapeuticsSAN-Sa13aNMES. aureusPre-clinical
Ultupharma ABULT13aNMEE. faecium, S. aureus, S. pneumoniae, Group A Streptococci / Complicated urinary tract infections (cUTI)IND/CTA ready
Ultupharma ABULT2C3aNMEE. coli, K. pneumoniae, Enterobacter spp., Salmonella spp., S. aureus, S. pneumoniae, H. influenzae, Group A Streptococci /Skin and Skin-structure infections (ABSSSI)IND/CTA ready
Ultupharma ABULT2B3aNMEE. coli, K. pneumoniae, Enterobacter spp., Salmonella spp., Shigella spp., H. influenzae / Cystic fibrosis associated infectionsIND/CTA ready
Ultupharma ABULT2A3aNMEE. coli, K. pneumoniae, Enterobacter spp., Salmonella spp., Shigella spp., S. aureus, H. influenzae / Cystic fibrosis associated infectionsIND/CTA ready
Ultupharma ABULT33aProtein/PeptideA. baumannii, E. coli, K. pneumoniae, Enterobacter spp., Other Enterobacterales, P. aeruginosa / Skin and Skin-structure infections (ABSSSI)IND/CTA ready
VAXDYNAcinetoVax1aVaccineA. baumannii / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Pre-clinical
VAXDYNEcoVax1aVaccineA. baumannii, E. coli / Bloodstream infectionsPre-clinical
VAXDYNP-Vax1aVaccineA. baumannii / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Pre-clinical
VAXDYNK-Vax1aVaccineA. baumannii, K. pneumoniae / Bloodstream infectionsIND/CTA ready
Epynext TherapeuticsEPY-0013aAntibodyP. aeruginosa / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Lead opt
Arivin therapeuticsViri-24253aNMEK. pneumoniae, P. aeruginosa / Chronic open woundsPre-clinical
Arivin therapeuticsViri-013aNMEK. pneumoniae, P. aeruginosa / Cystic fibrosis associated infectionsPre-clinical
Thioredoxin Systems ABEbsArgent3aNMEA. baumannii, P. aeruginosa, S. aureus / Complicated urinary tract infections (cUTI)IND/CTA ready
BioNTech R&DBNT3313aProtein/PeptideBacterial VaginosisIND/CTA ready
BasileaNovel target3aNMEE. faecium, S. aureus, S. pneumoniae / OsteomyelitisLead opt
BasileaNovel target (LptA inhibitor)3aNMEOther Enterobacterales (carbapenem-resistant) / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Lead opt
Nexbiome TherapeuticsBGA-19013aAntibodyH. piloriPre-clinical
Nexbiome TherapeuticsBGY-16013aAntibodyCandida spp and G. vaginalisIND/CTA ready
Nexbiome TherapeuticsNIN-21013aProtein/PeptideEnterococcus faecium, S. aureus / Hospital-acquired or Ventilator-acquired bacterial Pneumoniae (HABP/VABP)Lead opt
SurvivXSUR-1013cNMEImmune-oncology / SepsisIND/CTA ready
Infex Therapeutics LtdGON-X3aNMEN. Gonorrhoeae / Resistant Neisseria GonorrhoeaLead opt
Infex Therapeutics LtdVAP-X4aNMEP. aeruginosa / Hospital-acquired or Ventilator-acquired bacterial Pneumoniae (HABP/VABP)Lead opt
Disperazol Pharma ApSDisperazol3dNMEP. aeruginosa / Complicated urinary tract infections (cUTI)Pre-clinical
Disperazol Pharma ApSDisperazol1bNMEP. aeruginosa / Complicated urinary tract infections (cUTI)Pre-clinical
Osta TherapeuticsOsta 27OtherA. baumannii, P. aeruginosa, M. tuberculosis / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Pre-clinical
AUROBAC THERAPEUTICSATX4013aProtein/PeptideGram-negative pathogens / Treatment of HAP/VAP caused by Gram-negative bacteria as 1st line therapy suppressing AMR emergencePre-clinical
AUROBAC THERAPEUTICSATX1014aNMETreatment of early septic shock to prevent progression and improve outcomePre-clinical
NanoRevivStaph-EX3aOtherS. aureus, Group A Streptococci, Group B Streptococci / Skeletal InfectionsPre-clinical
PHAXIAMPP 1493 – PP 18153aPhageS. aureus IND/CTA ready
PHAXIAMPP 1493 – PP 18153aPhageS. aureus / EndocarditisIND/CTA ready
PHAXIAMPP 1450 – PP 1777 – PP 1797 – PP 17923aPhageP. aeruginosa / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)IND/CTA ready
PHAXIAMPP 970 – PP 1002 – PP 1151 – PP 20003aPhageComplicated urinary tract infections (cUTI)IND/CTA ready
PHAXIAMPP1493/PP18153aPhageEndocarditis with anti-S.aureus phage therapy Phase I
PHAXIAMPP1493/PP18153aPhageProsthetic Joint Infection (PJI) with anti-S.aureus phage therapy Phase II
discoveric bio betaNIDB-30023aNMEP. aeruginosa / Cystic fibrosis associated infectionsLead opt
discoveric bio betaNIDB-30013aNMEE. coli, K. pneumoniae / Bloodstream infectionsLead opt
Omnix MedicalOMN713aProtein/PeptideSalmonella spp., S. aureus / Skin and Skin-structure infections (ABSSSI)Pre-clinical
Omnix MedicalOMN513aProtein/PeptideEnterobacter spp., P. aeruginosa, S. aureus / Cystic Fibrosis associated infectionsPre-clinical
Destiny Pharma plcXF-731bNMEStaphylococcus aureus; Enterococcus faecium; Streptococcus pneumoniae / Prevention of oral mucositisPre-clinical
Destiny Pharma plcXF-733aNMEStaphylococcus aureus; Enterococcus faecium; Streptococcus pneumoniae / BurnsPre-clinical
Destiny Pharma plcXF-733aNMEStaphylococcus aureus; Enterococcus faecium; Streptococcus pneumoniae / Treatment of chronic rhinosinusitisPre-clinical
Destiny Pharma plcXF-733aNMEStaphylococcus aureus; Enterococcus faecium; Streptococcus pneumoniae / Cystic fibrosis associated infectionsPre-clinical
Destiny Pharma plcXF-733aNMEStaphylococcus aureus; Enterococcus faecium; Streptococcus pneumoniae / Prevention of post-surgical infectionPhase II
Destiny Pharma plcNTCD-M31bNMEToxigenic strains of C. difficile / Prevention of recurrence of C diff infectionPhase II
Destiny Pharma plcSPOR-COV1aNMERespiratory viruses, SARS-COV-2 & Influenza / Prevention of viral respiratory infectionsPre-clinical
Infex Therapeutics LtdRESP-X3cAntibodyP. aeruginosa / Non-cystic-fibrosis bronchiectasisPhase II
Infex Therapeutics LtdMET-X3dNMEA. baumannii, P. aeruginosa / Hospital-acquired or Ventilator-acquired bacterial Pneumoniae (HABP/VABP)IND/CTA ready
Infex Therapeutics LtdRDX-023aNMEGram-negative AMR infectionsLead opt
AdjuTec Pharma ASAPC2473dNMEE. coli, K. pneumoniae / Complicated urinary tract infections (cUTI)IND/CTA ready
F2G LtdOlorofim3aNMEDHODH inhibitor/Aspergillosis refractory, resistant or intolerant; Lomentospora prolificans, Scedosporium, Fusarium and Scopulariopsis species; Coccidioidomycosis refractoryPhase III
AdjuTec Pharma ASAPC1483dNMEK. pneumoniae; Enterobacter spp / complicated urinary tract infections (cUTI)Phase I
OLGRAMOL20015aProtein/PeptideP. aeruginosa; Broad-spectrum G+/G- / Cystic fibrosis associated infectionsPre-clinical
Selmod GmbHslm 5003aNMEE. coli; Broad-spectrum G+/G- / Complicated urinary tract infections (cUTI)IND/CTA ready
Selmod GmbHslm 3003aNMEK. pneumoniae; Broad-spectrum G+/G- / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Lead opt
Selmod GmbHslm 1003aNMECandida albicans, Aspergillus fumigatus, Candida auris / Invasive spergillosis, Oral Candidiasis, Bronchopulmonary aspergillosisaLead opt
Assuré Medical LimitedSol-UTI1bOtherP. aeruginosa, S.aureus / Uncomplicated urinary tract infections (uUTI)Pre-clinical
BioVersys AGBV1003aNMEA. baumannii / HAP, VAP, BSIPhase II
ABAC therapeuticsABAC-402443aNMES. aureus / Bloodstream infectionsLead opt
ABAC therapeuticsABAC-404113aNMES. pneumoniae / Community acquired pneumonia (CAP) and other upper respiratory infections (URTI) Lead opt
ANTABIO S.A.SSBLi (ANT3310)3dNMEA. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Citrobacter spp.; Proteus spp.; Salmonella spp; Shigella spp.; Other Enterobacterales; Haemophilus influenzae / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP) IND/CTA ready
VibioSphenVIKYNG3aOtherA. baumannii, P. aeruginosa, S. aureus / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)IND/CTA ready
QureTech Bio ABGmP3aNMEE. faecium, S. aureus / Skin and Skin-structure infections (ABSSSI)Lead opt
QureTech Bio ABMTI3aNMEMycobacterium tuberculosis / TuberculosisLead opt
Omnix MedicalOMN63a/5aProtein/PeptideA. baumannii, P. aeruginosa, E. coli, K. pneumoniae; Enterobacter spp / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Phase I
Northern Antibiotics Oy (Ltd)NAB8153aProtein/PeptideA. baumannii, E. coli, K. pneumoniae, Enterobacter spp., Salmonella spp., Shigella spp. / Complicated urinary tract infections (cUTI)Lead opt
Northern Antibiotics Oy (Ltd)NAB7393aProtein/PeptideA. baumannii, E. coli, K. pneumoniae, Enterobacter spp., Salmonella spp., Shigella spp. / Complicated urinary tract infections (cUTI)Lead opt
tamrisa2G-DAB3aNMEEnterobacterales, P. aeruginosa, A. baumannii/Complicated urinary tract infections (cUTI)Lead opt
tamrisaEBL-14633aNMEEnterobacterales/Complicated urinary tract infections (cUTI)Pre-clinical
IMMUNETHEP, SAUNImAb3cAntibodyE-coli, K. pneumoniae, S. aureus, S. pneumoniae, Group A Streptococci, Group B Streptococci / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Lead opt
IMMUNETHEP, SAPNV1aVaccineE-coli, K. pneumoniae, S. aureus, S. pneumoniae, Group A Streptococci, Group B Streptococci /Healthcare associated CAPIND/CTA ready
Hypharm GmbHHY-1331bPhageStaphylococcus aureus/Nasal colonization with MRSAPhase I
Eligo BioscienceEB0041bPhageEscherichia coli; Klebsiella pneumoniae/Bloodstream infectionsPre-clinical
Debiopharm InternationalDebio 14533aNMENeisseria gonorrhoeae / GonorrhoeaIND/CTA ready
Debiopharm InternationalAfabicin3aNMEStaphylococcus spp./ABSSSI (caused by S. aureus), bone and joint infectionsPhase II
Combioxin SACAL024aOtherVirulence factors, broad spectrum Gram+ and Gram-, resistance agnostic/Severe community-acquired bacterial pneumoniaPhase II
Centauri Therapeutics LtdABX013cOtherA. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp./Healthcare-asscoiated infectionsPre-clinical
Centauri Therapeutics LtdABX023cOtherP. aeruginosa/Healthcare-asscoiated infectionsPre-clinical
BioVersys AGBV2004aNMES. aureus / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Lead opt
BioVersys AGBV5003aNMEA. baumannii, S. aureus, Mycobacterium tuberculosis / Cystic fibrosis associated infectionsLead opt
BioVersys AGBVL-GSK0983dNMEM. tuberculosis/TuberculosisPhase I
BasileaCeftobiprole3aNMES. aureus (including MRSA); Streptococcus spp; Enterococcus faecalis; Enterobacterales; P. aeruginosa / Staphylococcus aureus bacteremia; Acute bacterial skin and skin structure infectionsPhase III
BasileaCeftobiprole3aNMES. aureus (including MRSA); Streptococcus spp; Enterococcus faecalis; Enterobacterales; P. aeruginosa; Haemophilus influenzae / CAP, HAPMarketed
ANTABIO S.A.SPEi (ANT3273)3cNMEP. aeruginosa / Non-CF bronchiectasis associated infectionsPre-clinical
ANTABIO S.A.SMBLi (ANT2681)3dNMEEscherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Citrobacter spp.; Proteus spp.; Salmonella spp; Shigella spp.; Other Enterobacterales; Haemophilus influenzae / Complicated urinary tract infections (cUTI)IND/CTA ready
ALLECRA THERAPEUTICSCefepime / Enmetazobactam3dNMEcUTI, APPhase III
AktheliaAKT-0113cNMEE. coli, Salmonella spp / Febrile NeutropeniaPre-clinical
ABAC therapeuticsABAC-398773aNMEA. baumannii / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Pre-clinical
PreviousPage 1/10show allNext

*BIC: BEAM Infection Curve

The displayed information are not necessarily reflecting the official current position of each BEAM members; please refer to each company’s website for updated information, or contact them directly.

Pipeline Dx

Click on column headers to sort the table

memberkit/testtargeted resultpathogens/indicationslab workflowdevelopment stage
OLM DiagnosticsDermatophyte LFAPathogen IDgenera Trichophyton, Microsporum, Epidermophyton /
Suspected dermatophyte infection of hair, skin or nails 		Other sample type
LFIA
<30 minutes		Prototype in Lab
OLM DiagnosticsOcular fungal infectionPathogen IDFusarium, Aspergillus and Candida /
Suspected Fungal keratitis. Risks for developing fungal keratitis include Recent eye trauma, particularly involving plants (for example, thorns or sticks), Underlying eye disease, Weakened immune system and Contact lens use		Other sample type
LFIA
<30 minutes		Prototype in Lab
OLM DiagnosticsOcular fungal infectionPathogen IDFusarium, Aspergillus and Candida /
Suspected Fungal keratitis. Risks for developing fungal keratitis include Recent eye trauma, particularly involving plants (for example, thorns or sticks), Underlying eye disease, Weakened immune system and Contact lens use		Other sample type
PCR/qPCR
<2h		Feasibility Phase
OLM DiagnosticsCocciIDPathogen IDCoccidioides immitis and C. posadasii /
Suspected lung infection in patient who has recently travelled to an endemic area.		From serum/plasma
PCR/qPCR
<2h		Feasibility Phase
OLM DiagnosticsHistoIDPathogen IDHistoplasma capsulatum /
Individuals with cellular immunity deficiencies, such as patients with HIV/AIDS infection. Mild respiratory illness in patients who have recently travelled to highly endemic regions		From serum/plasma
PCR/qPCR
<2h		Development Phase
OLM DiagnosticsMucorIDPathogen IDMucorales species; to include Rhizopus spp., Mucor spp., Lichtheimia spp., Cunninghamella spp., and Rhizomucor spp. /
Suspected fungal infection in patients predisposed by diabetes mellitus, corticosteroids and immunosuppressive drugs, primary or secondary immunodeficiency, hematological malignancies and hematological stem cell transplantation, solid organ malignancies and solid organ transplantation		From serum/plasma
PCR/qPCR
<2h		Development Phase
Microbira LtdMAAP-IRPathogen ID75% of Routine Clinical Isolates
Bacteria 94% correct identification: yeasts 95%		From isolated colony
Infrared spectroscopy
<30 minutes		CE-IVD and/or FDA 510k
Microbira LtdMicrobira PrototypeFrom PBS + Isolated colony
Infrared spectroscopy
<4h		Prototype in Lab
Microbira LtdMicrobira PrototypeFrom positive blood culture
Infrared spectroscopy
<30 minutes		Prototype in Lab
NosticsDUTIPathogen IDMultiplex bacteria
Urinary Tract infections		From urine
Surface Enhanced Raman Spectroscopy
<30 minutes		Feasibility Phase
MolsidfMicRapid antimicrobial susceptibility testAll
AST		From isolated colony
Proprietary reader
<4h		Feasibility Phase
MolsidPythia UTIAMR Mechanism of Resistance IDAll
From urine
Microplate-reader
<2h		Development Phase
MolsidPythia StaphAMR Mechanism of Resistance IDS. aureus
From isolated colony
Microplate-reader
<2h		Development Phase
PreviousPage 1/2show allNext

The displayed information are not necessarily reflecting the official current position of each BEAM members; please refer to each company’s website for updated information, or contact them directly.